The HLA complement-dependent cytotoxicity (CDC) assay detects the binding of recipient antibodies to donor cells. This assay is performed as part of a pre-transplant immunology risk assessment to help determine the compatibility of donor-recipient pairs. In this recorded webinar, Petrina Fan describes the use of EasySep™ Serology CD3 and CD19 positive cell selection on RoboSep™-S for the CDC assay and provides information for validating these products for an optimized protocol. By the end of this webinar, the attendees will be familiar with the process involved in validating the CDC assay, the CDC assay protocol, and the automated isolation of T and B cells from whole blood. You can claim 0.15 ACHI continuing education credits (CECs) after viewing this webinar.
November 24, 2021
Request Webinar Form
Thank you for your interest in this product.
Please provide us with your contact information and your local representative
will contact you with a customized quote. Where appropriate, they can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
. Please contact us
with any questions that you may have. You can unsubscribe or change your email preferences
at any time.